Inhalation Anesthesia Market

Market Definition:

Global Inhalation Anesthesia Market size was valued at USD 1.31 billion in 2021 and is predicted to reach USD 1.88 billion by 2030 with a CAGR of 4.1% from 2022 to 2030. Inhalation anesthesia refers to volatile anesthetic agents that are utilized for maintaining the level of sedation during surgery. This anesthesia is given to patients through the route of inhalation that have limited tolerance and addiction level. They are highly effective if given in small doses and help induce respiratory depression, reduce arterial blood pressure, and rise cerebral metabolic demand. Moreover, these drugs have lower risk of delirium and are cost-effective.

Market Dynamics and Trends:

The demand for inhalation anesthesia is increasing due to rising prevalence of cardiovascular and respiratory system-related diseases. Also, factors such as, prevalence of chronic medical disorders that require surgical treatments and rise in the number of accidents and emergency casesare expected to propel the growth of the market during the forecast period. Moreover, rise in incidences of various chronic diseases including infectious diseases, genetic disorders, and cancer due to unhealthy lifestyle are anticipated to boost the inhalation anesthesia market demand during the forecast period.

However, postoperative nausea and vomiting as well as reluctance from physicians for its usage are factors expected to restrain the growth of the market to certain extent. On the other hand, development of innovativetechnologies, such as anesthesia recycling systems that can be used for extracting anesthetic compounds from operating rooms and hospital vents, areexpected to create lucrative growth opportunities for the inhalation anesthesia market players in future.

Market Segmentations and Scope of the Study:

The inhalation anesthesia market has been segmented based on product, application, end-use, and geography. Based on product, the market is bifurcated into sevoflurane, desflurane, isoflurane, and nitrous oxide. Based on application, the market is divided into induction and maintenance. Based on end-user, the market is bifurcated into hospitals and ambulatory surgical center. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

Asia-Pacific region holds the lion share of inhalation anesthesia market and is expected to continue dominating the market during the forecast period. This is attributed to factors such as expanding population, availability of healthcare insurance for masses, and increasing expenditure in healthcare sector Moreover, increasing medical tourism due to the availability of advanced as well as cost-efficient treatments is propelling the demand of the market in this region.

North America, on the other hand is expected to show a steady rise in the inhalation anesthesia market due to increased number of lifestyle diseases such as obesity and respiratory disorder. Also, rise in government investments for R&D, and surging healthcare expenditure are contributing towards the growth of the market. Moreover, increasing demand for surgeries such as ambulatory surgery and inpatient surgery will boost demand for inhalation anesthesia market in this region.

Competitive Landscape:

The market comprises of various players such as Baxter, Piramal Enterprises Ltd., Halocarbon Life Sciences, LLC., Lunan Pharmaceutical Group, Abbvie Inc., Hikma Pharmaceuticals PLC, Dechra Pharmaceuticals PLC, Maruishi Pharmaceutical Co.,Ltd., Troikaa Pharmaceuticals Ltd, Fresenius Kabi AG. These manufacturers are actively indulging in R&D initiatives, product & technology innovations, and industrial collaborations to enhance their product and increase their growth as well as geographical reach. For instance, in June 2020, Piramal Enterprises Ltd has announced a partnership with Medivant Healthcare. The aim of this partnership was to distribute single-dose injectable drugs (inhalation anesthesia) to hospitals for the COVID-19 patients, which have fallen short in supply. Also, in July 2021, Hikma Pharmaceuticals announced that they have launched a succinylcholine chloride injection, in the United States through its U.S. subsidiary. In addition to general anesthesia, thiswill help in aiding tracheal intubation and give skeletal muscle relaxation during surgery.

Key Benefits:

• The inhalation anesthesia market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the inhalation anesthesia market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints and opportunities and their impact on the inhalation anesthesia market is provided in the report.

• The competitive analysis of the market players along with their market share in the inhalation anesthesia market

• The SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Key Market Segments:

By Product Type

• Sevoflurane

• Desflurane

• Isoflurane

• Nitrous Oxide

By Application

• Induction

• Maintenance

By End-User

• Hospitals

• Ambulatory Surgical Centers

• Other End Users

By Geography

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The UK

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia        

  • Rest of Europe    

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia Pacific

• RoW

  • Latin America

  • Middle East

  • Africa

Key Players:

• Baxter

• Piramal Enterprises Ltd.

• Halocarbon Life Sciences, LLC.

• Lunan Pharmaceutical Group 

• Abbvie Inc.

• Hikma Pharmaceuticals PLC

• Dechra Pharmaceuticals PLC

• Maruishi Pharmaceutical Co.,Ltd.

• Troikaa Pharmaceuticals Ltd

• Fresenius Kabi AG

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2021–2030
Base Year Considered	2021
Forecast Period	2022–2030
Market Size Estimation	Billion (USD)
Market Segmentation	By Product (Sevoflurane, Desflurane, Isoflurane, and Nitrous Oxide), Application (Induction and Maintenance), and by End-User (Hospitals and Ambulatory Surgical Centers)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Germany, France, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, Rest of Asia-Pacific), Rest of the World (Latin America, Middle east, Africa)
Companies Profiled	Hikma Pharmaceuticals PLC, Abbvie Inc., Baxter International Inc., Piramal Enterprises Ltd., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd.